A post-approval and GMP inspection of this foreign drug substance and drug product manufacturer was conducted per FY17 work plans. The firm manufactures one product for the US market, Inflectra (infliximab-dyyb) under BLA 125544. Coverage was given to compliance program 7346.843, Post-Approval Inspections, compliance program 7356.002A, Sterile Drug Process Inspections, and
compliance program 7356.002M, Inspections of Licensed Biological Therapeutic Drug Products. The Quality, Facilities & Equipment, Production, and Laboratory systems received coverage.
Continue at: https://www.pharmacompass.com/jAssets/pdf/news/FDA-Issues-EIR-to-Celltrion-Inc-1522487709.pdf
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link